E-cigarettes popularity forces firms to review policies

November 11, 2013

ecigar

When John Castellano feels like a smoke, he simply heads to the break room at Kraft Foods’s factory in Garland, Texas.

The technician has been able to indulge his habit in common areas at work since he started using electronic cigarettes, which emit vapor rather than smoke.

E-cigarettes are “very liberating,” said Castellano, 39, who used to join the other cigarette addicts at the factory’s designated smoking area.

Twenty-five years after companies began banning smoking in the workplace, the increasing popularity of e-cigarettes is forcing them to review their policies.

Many corporations still ban “vaping” as they wait to see if the FDA will regulate e-cigarettes as strictly as regular smokes. Yet Kraft and Walgreen allow local managers to set the rules. Smaller firms, especially creative agencies and Web startups, have already adopted a more laissez-faire attitude.

US e-cigarettes sales will triple this year to $1.5 billion, according to Euromonitor International. They’re expected to accelerate as traditional tobacco makers muscle into a market previously dominated by small players.

Both Altria Group and Reynolds American, the biggest US tobacco sellers, are expanding distribution of e-cigarettes. Lorillard controls about half of the USmarket with blu eCigs, which it acquired last year.

So far, small companies where bosses can monitor whether e-cigarettes bother co-workers are more likely to allow vaping.

“It is all new to us,” said Ged King, president of the Sales Factory, a 35-employee marketing firm based here. He looked up in surprise during a staff meeting a few months ago to see an employee vaping. Now several employees do it, presumably “to help them kick the smoking habit,” he said.

“We’ve not put a policy in place because nobody has complained,” King said.

The technology gives users seeking anonymity an edge. E-cigarettes heat liquid nicotine into an inhaled vapor, dissipating faster than cigarette smoke. So workers more worried about being seen than smelled puff e-cigarettes in empty offices and bathrooms, according to posts on the E-Cigarette Forum website, where visitors share favorite flavors and vaping lounges, plus tips on how to avoid offending co-workers.

“I’m doing it on the down-low and just close the door,” said Dennis Rumpf, a construction manager in Charlotte, N.C. He declined to identify his employer because it didn’t authorize him to speak publicly.

Rumpf, 37, said he alternates between menthol and classic tobacco flavors in the e-cigarettes he’s been using for six months, after 19 years as a smoker.

“I have people come into my office all the time and I’m sure they’d say something if they noticed anything,” he said.

Web developer Adam Gray has won his boss’s approval to use e-cigarettes at his Minnetonka, Minnesota, office.

“It makes him more productive and sets him on a path for better health,” said Paul Hanson, chief operating officer of TrackIF LLC, a firm that monitors price changes across the Web.

Gray, 27, can “vape all day, a puff here and there” without leaving his desk, he said.

Kraft doesn’t have a companywide e-cigarettes policy and allows managers to make their own rules as long as they abide by local and state laws. Walgreen, the largest US drugstore retailer, also leaves decisions to office managers.

However, health and regulatory uncertainties have prompted many employers to treat e-cigarettes like regular cigarettes, said Paula Andersen, a registered nurse at Buck Consultants, a human- resources firm that advises companies on health programs.

“We recommend that if companies do have a tobacco-free policy that they call electronic cigarettes out as well,” said Andersen, who declined to identify clients.

Exxon Mobil and General Motors allow vaping in designated smoking areas, while CVS Caremark and Lowe’s ban e-cigarettes and regular smokes. Levi Strauss & Co. forces vapers to go outside.

“For the most part, people who vape are treated as smokers,” said LeeAnn Blohm, who favors chocolate peanut butter and butterscotch e-cigarettes. She declined to identify her employer in Austin, Texas, which doesn’t allow vaping inside.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 4,2020

Boston, Feb 4: Practising yoga may increase levels of a messenger molecule involved in regulating brain activity, and completing one yoga class per week may maintain elevated levels of this chemical, according to a study which may lead to better ways of mitigating depressive symptoms.

The study, published in the Journal of Alternative and Complementary Medicine, assessed a group of 30 clinically depressed patients who were randomly divided into two groups.

According to the researchers, including those from Boston University in the US, both groups engaged in coherent breathing, and Iyengar yoga -- a form of hatha yoga, developed by B. K. S. Iyengar, emphasising on detail, precision, and alignment in the performance of yoga postures.

The only difference between the groups, the scientists said, was the number of 90 minute yoga sessions, and home sessions in which each group participated.

Over three months, they said, the high-dose group (HDG) was assigned three sessions per week, while the low-intensity group (LIG) engaged in two sessions per week.

The participants underwent magnetic resonance imaging (MRI) scans of their brain before the first and after the last yoga session, and also completed a clinical depression scale to monitor their symptoms, the study noted.

Results of the study revealed that both groups had improvement in depressive symptoms after three months.

Their MRI analysis showed that levels of the brain messenger molecule GABA were elevated after three months of yoga, as compared to the levels before starting yoga.

According to the study, this increase was found for approximately four days after the last yoga session, but the rise was no longer observed after about eight days.

"The study suggests that the associated increase in GABA levels after a yoga session are 'time-limited' similar to that of pharmacologic treatments such that completing one session of yoga per week may maintain elevated levels of GABA," explained study co-author Chris Streeter from Boston University.

Providing evidence-based data may help in getting more individuals to try yoga as a strategy for improving their health and well-being, the scientists said.

"A unique strength of this study is that pairing the yoga intervention with brain imaging provides important neurobiological insight as to the 'how' yoga may help to alleviate depression and anxiety," said study co-author Marisa Silveri from Harvard University.

In this study, we found that an important neurochemical, GABA, which is related to mood, anxiety, and sleep, is significantly increased in association with a yoga intervention," Silveri said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 10,2020

Early treatment with the antiviral drug remdesivir has been found to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2 that causes COVID-19, according to a study.

The findings, published in the journal Nature on Tuesday, support the early use of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.

Researchers from the National Institutes of Health in the US noted that remdesivir has broad antiviral activity and has been shown to be effective against infections with SARS-CoV and MERS-CoV in animal models.

The drug is being tested in human clinical trials for the treatment of COVID-19, they said.

Researcher Emmie de Wit and colleagues investigated the effects of remdesivir treatment in rhesus macaques, a recently established model of SARS-CoV-2 infection.

Two sets of six macaques were inoculated with SARS-CoV-2.

One group was treated with remdesivir 12 hours later -- close to the peak of virus reproduction in the lungs -- and these macaques received treatment every 24 hours until six days after inoculation.

In contrast to the control group, the researchers found that macaques that received remdesivir did not show signs of respiratory disease, and had reduced damage to the lungs.

Viral loads in the lower respiratory tract were also reduced in the treated animals; viral levels were around 100 times lower in the lower-respiratory tract of remdesivir-treated macaques 12 hours after the first dose, they said.

The researchers said that infectious virus could no longer be detected in the treatment group three days after initial infection, but was still detectable in four out of six control animals.

Despite this virus reduction in the lower respiratory tract, no reduction in virus shedding was observed, which indicates that clinical improvement may not equate to a lack of infectiousness, they said.

Dosing of remdesivir in the rhesus macaques is equivalent to that used in humans, the researchers noted.

They cautioned that it is difficult to directly translate the timing of treatment used in corresponding disease stages in humans, because rhesus macaques normally develop only mild disease.

However, researchers said the results indicate that remdesivir treatment of COVID-19 should be initiated as early as possible to achieve the maximum treatment effect.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 16,2020

New Delhi, Mar 16: A recent survey across 140 districts of the country shows that about 54 per cent of Indians are finding travelling to be unsafe as the deadly coronavirus (COVID-19) pandemic sweeps globally.

The big worry that people have is community transmission, something that researchers from around the world have approximated at 10 per cent of total infections and more common in places like Wuhan in China, South Korea, Iran and Italy.

The months of March to June have historically been high travel season for most Indians, largely due to the summer vacations in schools. "But it seems that Indians do not want to take a chance with this rather scary virus and are either cancelling or postponing their travel plans," concluded the survey by LocalCircles.

The survey gathered more than 22,000 responses from participants in tier one, two and three cities. It said 48 per cent Indians plan to cancel their international business travel for the next four months.

Besides, nearly 38 per cent of respondents said they had to pay cancellation fee to the website, travel agent, airline or railways.

"These are testing times for the entire travel and tourism industry -- airlines, hotels, travel agents as well as small tour and taxi operators. The best solution at this point is to adjust cost structures, stay flexible and work with a collective approach to minimise the period of impact to both citizens and business," said LocalCircles.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.